Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site

被引：1

作者：

Ribeiro, J. T. M. L.

Ali, S. M.

Correia, L.

Luis, I. M. V. D.

Matias, M.

Amaral, T.

Quintela, A. A. F. G.

Leitzel, K.

Lipton, A.

Costa, L.

机构：

[1] Hosp Santa Maria, Dept Oncol, Lisbon, Portugal

[2] Univ Lisbon, Inst Mol Med, P-1699 Lisbon, Portugal

[3] Lebanon VA Med Ctr, Penn State Hershey Med Ctr, Hershey, PA USA

[4] Hosp Santa Maria, Dept Pathol, Lisbon, Portugal

[5] Penn State Hershey Med Ctr, Hershey, PA USA

[6] Hosp Santa Maria, Dept Oncol, CHLN, Lisbon, Portugal

[7] IMM, Clin & Translat Oncol Res Unit, Lisbon, Portugal

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.e11114

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e11114

引用

页数：1

共 50 条

[1] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
Fehm, T.
Solomayer, E.
Uhr, J.
Wallwiener, D.
ONKOLOGIE, 2008, 31 : 51 - 51
[2] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
Fehm, T.
Lane, N.
Solomayer, E.
Wallwiener, D.
Uhr, J.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
[3] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Fehm, Tanja
Becker, Sven
Duerr-Stoerzer, Silke
Sotlar, Karl
Mueller, Volkmar
Wallwiener, Diethelm
Lane, Nancy
Solomayer, Erich
Uhr, Jonathan
BREAST CANCER RESEARCH, 2007, 9 (05) : R74
[4] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm
Sven Becker
Silke Duerr-Stoerzer
Karl Sotlar
Volkmar Mueller
Diethelm Wallwiener
Nancy Lane
Erich Solomayer
Jonathan Uhr
Breast Cancer Research, 9
[5] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
Shah, Mirat
Ensminger, Jennifer
Wang, Chenguang
Ali, Siraj
Chung, Jon
Lauring, Josh
Park, Ben Ho
Stearns, Vered
CANCER RESEARCH, 2020, 80 (04)
[6] Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Kurbacher, C. M.
Quade, A.
Eichler, C.
Kunstmann, G.
Herz, S.
Kurbacher, J. A.
Warm, M. R.
CANCER RESEARCH, 2016, 76
[7] Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
Kurbacher, C. M.
Quade, A.
Kunstmann, G.
Herz, S.
Kurbacher, J. A.
Warm, M. A.
ANNALS OF ONCOLOGY, 2015, 26
[8] Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer
Kong, Sun-Young
Nam, Byung-Ho
Lee, Keun Seok
Kwon, Youngmee
Lee, Eun Sook
Seong, Moon-Woo
Lee, Do Hoon
Ro, Jungsil
CLINICAL CHEMISTRY, 2006, 52 (08) : 1510 - 1515
[9] HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
Endo, Yumi
Dong, Yu
Yoshimoto, Nobuyasu
Asano, Tomoko
Hato, Yukari
Yamashita, Hiroko
Sato, Shinya
Takahashi, Satoru
Fujii, Yoshitaka
Toyama, Tatsuya
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (07) : 619 - 623
[10] When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
Miles, David W.
BREAST CANCER RESEARCH, 2009, 11 (04)

← 1 2 3 4 5 →